ArticleJournal of the American Heart Association2025
Evaluating the Science of Diversity in Clinical Trials: Design and Goals of an American Heart Association Strategic Focused Research Network.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Third Year in Review, Fourth Year in Preview, and the 2025Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundClinical trials serve as the key evidence that shapes guideline recommendations and clinical practice. Despite long-standing recommendations by regulatory and funding organizations for representative trial enrollment, the underinclusion of women and individuals from diverse racial and ethnic populations in cardiovascular and dementia clinical trials persists. This undermines trust in research, threatens basic principles of fairness, and may limit the generalizability of trial results to broad patient populations.
methodsTo better understand how to foster more inclusive cardiovascular trial participation, the American Heart Association launched a Strategically Focused Research Network (SFRN) to study the Science of Diversity in Clinical Trials in 2022. The SFRN includes 5 Network Centers operating from Johns Hopkins University ("IMPACT"), Stanford University ("DIVERSE"), University of California Los Angeles ("iDIVERSE"), University of Southern California/Howard University ("ATRIL"), and the University of Pennsylvania ("BETTER"). Each Center is a partnership that includes an institution focused on the education of Black, Hispanic, American Indian, Native Hawaiian/Pacific Islander, and/or non-White students. Each Center has multiple projects with actionable results and is training at least 3 dedicated postdoctoral fellows. Additionally, a 6th Center ("TRAIN") led by faculty at Stanford and Morehouse Universities is facilitating formal fellowship training across the Centers.
conclusionsProjects are ongoing and all 6 Centers are working on collaborative initiatives. These Centers are expected to provide valuable insights into clinical trial participation, including innovative conceptual frameworks to inform the diversification of clinical trial participation and novel recruitment and retention strategies that can be broadly disseminated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.